vimarsana.com
  1. Home
  2. Live Updates
  3. Michael Petusky - Breaking News

Latest Breaking News On - Michael petusky - Page 1 : vimarsana.com

SRDX Alert: Monsey Firm of Wohl & Fruchter Investigating

We are investigating the fairness of the sale of Surmodics to GTCR for $43.00 per share in cash.

Joshuae fruchterWohl fruchterMichael petuskyJoshua fruchterSurmodics incWall streetSurmodics boardLake street

Opko Health (OPK) Q1 2024 Earnings Call Transcript

Opko Health (OPK) Q1 2024 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesNew jerseyPiper sandlerTed tenthoff piper sandlerMichael petuskyPhillip frostElias zerhouniMaury raycroftYale jenYale jen laidlawEdward tenthoffJeffrey cohen ladenburg thalmannGary nabelJeff cohenYi chen

Critical Insights From OPKO Health Analyst Ratings: What You Need To Know

Across the recent three months, 4 analysts have shared their insights on OPKO Health (NASDAQ:OPK), expressing a variety of opinions spanning from .

Michael petuskyEdward tenthoffYi chenPiper sandlerBarrington researchHc wainwright coHealth incAnalyst firmHealth careAnalyst ratingsStory behindCapitalization analysisWhat are

Buy Rating Affirmed for Opko Health Amid Strategic Divestiture and Operational Improvement Prospects

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health (OPK – Research Report), with a price t.

Piper sandlerMichael petuskyOpko healthResearch reportTipranks premium

LeMaitre Vascular, Inc (NASDAQ:LMAT) Q4 2023 Earnings Call Transcript

LeMaitre Vascular, Inc. beats earnings expectations. Reported EPS is $0.38, expectations were $0.36. LeMaitre Vascular, Inc.

United statesKrung thep mahanakhonBruxelles capitaleSoult ukpyolsiSouth koreaFrance generalMichael petuskyDaniel stauderSuraj kaliaAsia pacDave robertsJames sidotiGeorge lemaitreRick wiseLemaitre vascularBarrington research

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.